Association between ulcerative growth and hypoxia inducible factor-1α polymorphisms in colorectal cancer patients

Molecular Carcinogenesis

Volumn 45, Issue 11, 2006, Pages 833-840

  Fransén, Karin ^a   Fenech, Matthew ^a   Fredrikson, Mats ^b   Dabrosin, Charlotta ^b   Söderkvist, Peter ^a  

^a LINKÖPING UNIVERSITY   (Sweden)

^b LINKÖPING UNIVERSITY HOSPITAL   (Sweden)

Author keywords

Colorectal cancer; HIF; Hypoxia; Polypoid; Ulcerative

Indexed keywords

HYPOXIA INDUCIBLE FACTOR 1ALPHA;

ADULT; AGED; ALLELE; ANGIOGENESIS; ARTICLE; COLORECTAL CANCER; DISEASE SEVERITY; DNA POLYMORPHISM; FEMALE; GENETIC ASSOCIATION; HIGH RISK PATIENT; HOMOZYGOSITY; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; MAJOR CLINICAL STUDY; MALE; NUCLEOTIDE SEQUENCE; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; RESTRICTION FRAGMENT LENGTH POLYMORPHISM; SINGLE STRAND CONFORMATION POLYMORPHISM; ULCER; WILD TYPE;

ADULT; AGED; AGED, 80 AND OVER; AMINO ACID SEQUENCE; BASE SEQUENCE; COLORECTAL NEOPLASMS; DNA PRIMERS; EVOLUTION, MOLECULAR; FEMALE; HUMANS; HYPOXIA-INDUCIBLE FACTOR 1, ALPHA SUBUNIT; IMMUNOHISTOCHEMISTRY; LOSS OF HETEROZYGOSITY; MALE; MIDDLE AGED; MOLECULAR SEQUENCE DATA; POLYMERASE CHAIN REACTION; POLYMORPHISM, GENETIC; POLYMORPHISM, RESTRICTION FRAGMENT LENGTH; SEQUENCE HOMOLOGY, AMINO ACID; ULCER;

EID: 33750489434     PISSN: 08991987     EISSN: 10982744     Source Type: Journal    
DOI: 10.1002/mc.20209     Document Type: Article

References (32)

1. Semenza GL, Rue EA, Iyer NV, Pang MG, Kearns WG. Assignment of the hypoxia-inducible factor 1 alpha gene to a region of conserved synteny on mouse chromosome 12 and human chromosome 14q. Genomics 1996;34:437-439.
2. Thorstensen L, Qvist H, Nesland JM, Giercksky KE, Lothe RA. Identification of two potential suppressor gene regions on chromosome arm 14q that are commonly lost in advanced colorectal carcinomas. Scand J Gastroenterol 2001;12:1327-1331.
3. Gallou C, Mejean A, Bouvier R, et al. Delineation of a 2.8 megabases region harboring a potential tumor suppressor gene involved in renal cell carcinoma, that is commonly deleted from chromosome 14. Anticancer Res 2003;23:4865-4870.
4. Dichamp C, Taillibert S, Aguirre-Cruz L, et al. Loss of 14q chromosome in oligoendroglial and astrocytic tumors. J Neuro oncol 2004;67:281-285.
5. Wang GL, Jiang BH, Rue EA, Semenza GL. Hypoxia-inducible factor 1 is a basic-helix-loop-helix-PAS heterodimer regulated by cellular O2 tension. Proc Natl Acad Sci USA 1995;92:5510-5514.
6. Semenza GL. Targetin Hif-1 for cancer therapy. Nat Rev Cancer 2003;3:721-732.
7. Kimura H, Weisz A, Kurashima Y, et al. Hypoxia response element of the human vascular endothelial growth factor gene mediates transcriptional regulation by nitric oxide: Control of hypoxia-inducible factor-1 activity by nitric oxide. Blood 2000;95:189-197.
8. Kimura H, Weisz A, Ogura T, et al. Identification of hypoxia-inducible factor-1 (HIF-1) ancillary sequence and its function in vascular endothelia growth factor gene induction by hypoxia and nitric oxide. J Biol Chem 2001;276:2292-2298.
9. Mellilo G, Musso T, Sica A, Taylor LS, Cox GW, Varesio LA. A hypoxia-responsive element mediates a novel pathway of activation of the inducible nitric oxide synthase promoter. J Exp Med 1995;182:1683-1693.
10. Maxwell PH, Wiesener MS, Chang GW, et al. The tumor suppressor protein VHL targets hypoxia-inducible factors for oxygen-dependent proteolysis. Nature 1999;399:271-275.
11. Jaakkola P, Mole DR, Tian YM, et al. Targeting of HIF-alpha to the von Hippel-Lindau ubiquitylation complex by O2-regulated prolyl hydroxylation. Science 2001;292:468-472.
12. 2 sensing. Science 2001;292:464-468.
13. Masson N, William C, Maxwell PH, Pugh CW, Ratcliffe PJ. Independent function of two destruction domains in hypoxia-inducible factor α chains activated by prolyl hydroxylation. EMBO J 2001;20:5197-5206.
14. Min JH, Yang H, Ivan M, Gertler F, Kaelin WG, Jr., Pavletich NP. Structure of an HIF-1 alpha-pVHL hydroxyproline recognition in signaling. Science 2002;296:1886-1889.
15. Hansson LO, Friedler A, Feund S, Rüdinger S, Fersht AR. Two sequence motifs from HIF-1α bind to the DNA binding site of p53. Proc Natl Acad Sci 2002;99:10305-10309.
16. Clifford SC, Astuti D, Hooper L, Maxwell PH, Ratcliffe PH, Maher ER. The pVHL associated SCF ubiquitin ligase complex: Molecular genetic analysis of elongin B and C, Rbx1 and HIF-1α in renal cell carcinoma. Oncogene 2001;20:5067-5074.
17. Tanimoto K, Yoshiga K, Eguchi H, et al. Hypoxia-inducible factor 1a polymorphisms associated with enhanced transactivation capacity, implying clinical significance. Carcinogenesis 2003;24:1779-1783.
18. Fransen K, Dimberg J, Österström A, Olsson A, Söderkvist P, Sirsjö A. Nitric oxide synthase 2 mRNA expression in relation to p53 and adenomatous polyposis coli mutations in primary colorectal adenocarcinomas. Surgery 2002;131:384-392.
19. Schor AM, Pendleton N, Pazouki S, et al. Assessment of vascularity in histological sections: Effects of methodology and value as an index of angiogenesis in breast tumours. Histochem J 1998;30:849-856.
20. Higgins D, Thompson J, Gibson T, Thompson JD, Higgins DG, Gibson TJ. CLUSTAL W: Improving the sensitivity of progressivemultiple sequence alignment through sequence weighting, position-specific gap penalties and weight matrix choice. Nucleic Acids Res 1994;22:4673-4680.
21. Nasir A, Boulware D, Kaiser HE, et al. Flat and polypoid adenocarcinoas of the colorectum: A comparative histomorphologic analysis of 47 cases. Hum Pathol 2004;35:604-611.
22. Elson DA, Ryan HE, Snow JW, Johnson R, Arbeit JM. Coordinate up-regulation of hypoxia inducible factor (HIF)-1 alpha and HIF-1 target genes during multi-stage epidermal carcinogenesis and wound healing. Cancer Res 2000;60:6189-6195.
23. Giatromanolaki A, Sivridis E, Maltezos E, et al. Hypoxia inducible factor 1alpha and 2alpha overexpression in inflammatory bowel disease. J Clin Pathol 2003;56:209-213.
24. Gradin K, Takasaki C, Fujii-Kuriyama Y, Sogawa K. The transcriptional activation function of the HIF-like factor requires phosphorylation at a conserved threonine. J Biol Chem 2002;277:23508-23514.
25. Chan DA, Sutphin PD, Denko NC, Giaccia AJ. Role of prolyl hydroxylation in oncogenically stabilized hypoxia-inducible factor-1 alpha. J Biol Chem 2002;277:40112-40117.
26. Smith G, Carey FA, Beattie J, et al. Mutations in APC, Kirstenras, and p53-Alternative genetic pathways to colorectal cancer. Proc Natl Acad Sci USA 2002;99:9433-9438.
27. Davies H, Bignell GR, Cox C, et al. Mutations of the BRAF gene in human cancer. Nature 2002;417:949-954.
28. Samuels Y, Wang Z, Bardelli A, et al. High frequency of mutations of the PIK3CA gene in human cancers. Science 2004;304:554.
29. Zhou XP, Loukola A, Salovaara R, et al. PTEN mutational spectra, expression levels, and subcellular localization in microsatellite stable and unstable colorectal cancers. Am J Pathol 2002;161:439-447.
30. Nassif NT, Lobo GP, Wu X, et al. PTEN mutations are common in sporadic microsatellite stable colorectal cancer. Oncogene 2004;23:617-628.
31. Kageyama Y, Koshiji M, To KK, Tian YM, Ratcliffe PJ, Huang/ SNM> LE. Leu-574 of human HIF-1alpha is a molecular determinant of prolyl hydroxylation. FASEB J 2004;18:1028-1030.
32. Percy MJ, Mooney SM, McMullin MF, Flores A, Lappin TRJ, Lee FS. A common polymorphism in the oxygen dependent degradation (ODD) domain of hypoxia inducible factor-1a (HIF-1α) does not impair Pro-564 hydroxylation. Mol Cancer 2003;2:31.